BioReliance appoints Dr James Kramer VP of global biologics operations
This article was originally published in Scrip
BioReliance, a contract services company that provides biologics safety testing, toxicology, viral manufacturing and laboratory animal diagnostic services to the pharmaceutical and biopharmaceutical industries worldwide, has appointed Dr James Kramer to the newly created position of vice-president of global biologics operations. He joined the company in December 2007 as vice-president of operations, US biologics.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.